blessing/09829026

(FILE 'HOME' ENTERED AT 17:00:17 ON 05 JAN 2002)

FILE 'ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, PASCAL, ...' ENTERED AT 17:00:30 ON 05 JAN 2002

L1	5747	S	DYSLIPIDEMIA (S) TREAT?
L2	38872	S	ATORVASTATIN OR PRAVASTATIN OR HMG(W)COA REDUCTASE INHIBITOR
L3	4959800	S	COMPOSITION OR FORMULATION
L4	91441	S	PVP OR POLYVINYLPYRROLIDONE OR POLYVINYL PYRROLIDONE
L5	29	S	L4 (S) L2
L6	0	S	L5 AND L1
L7	638	S	L1 AND L2
L8	69	S	L7 AND L3
L9	17496	S	CHOLESTYRAMINE
L10	23	S	L8 AND L4
L11	13	S	L10 AND L9
L12	2	S	L5 AND L9

L12 ANSWER 1 OF 2 USPATFULL
ACCESSION NUMBER: 2000:168044 USPATFULL
TITLE: Treatment of arteriosclerosis and xanthoma
INVENTOR(S): Tsujita, Yoshio, Tokyo, Japan
Horikoshi, Hiroyoshi, Tokyo, Japan
Shiomi, Masashi, Kobe, Japan
Ito, Takashi, Kobe, Japan
PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6159997		20001212
APPLICATION INFO.:	US 1998-61446		19980416 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-676090, filed on 2 Jul 1996, now patented, Pat. No. US 5798375

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-167291	19950703

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.
NUMBER OF CLAIMS: 210
EXEMPLARY CLAIM: 1
LINE COUNT: 1910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride,

5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 2 USPATFULL
ACCESSION NUMBER: 1998:101666 USPATFULL
TITLE: Treatment of arteriosclerosis and xanthoma
INVENTOR(S): Tsujita, Yoshio, Tokyo, Japan
Horikoshi, Hiroyoshi, Kobe, Japan
Ito, Takashi, Kobe, Japan
PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE

blessing/09829026

PATENT INFORMATION:	US 5798375	19980825
APPLICATION INFO.:	US 1996-676090	19960702 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-167291	19950703

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, Esq.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]-ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-yl-methoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy) benzyllthiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

blessing/09829026

L11 ANSWER 1 OF 13 USPATFULL
ACCESSION NUMBER: 2002:4170 USPATFULL
TITLE: Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
INVENTOR(S): Bayly, Christopher, Beaconsfield, CANADA
Ohkubo, Mitsuru, Ushiki, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002002149	A1	20020103
APPLICATION INFO.:	US 2001-813499	A1	20010321 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191369	20000322 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 1768
AB The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme.
##STR1##

The invention also encompasses pharmaceutical **compositions** and methods of treating or preventing PTP-1B mediated diseases, including diabetes.

L11 ANSWER 2 OF 13 USPATFULL
ACCESSION NUMBER: 2001:226598 USPATFULL
TITLE: Method of treating septic shock
INVENTOR(S): Dasseux, Jean-Louis, Mannheim, Germany, Federal Republic of
Sekul, Renate, Ladenburg, Germany, Federal Republic of
Buttner, Klaus, Epfenbach, Germany, Federal Republic of
Cornut, Isabelle, Edingen-Neckarhausen, Germany, Federal Republic of
Metz, Gunther, Edingen-Neckarhausen, Germany, Federal Republic of
Dufourcq, Jean, Pessac, France
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., Ann Arbor, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6329341	B1	20011211
APPLICATION INFO.:	US 1999-453605		19991201 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-940095, filed on 29 Sep 1997, now patented, Pat. No. US 6004925
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Celsa, Bennett
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 4707
AB The present invention provides peptides and petptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to **treat** a variety of disorders associated with **dyslipidemia**.

L11 ANSWER 3 OF 13 USPATFULL
ACCESSION NUMBER: 2001:205916 USPATFULL
TITLE: New compounds, their preparation and use
INVENTOR(S): Mogensen, John Patrick, Herlev, Denmark
Sauerberg, Per, Farum, Denmark
Bury, Paul Stanley, Kobenhavn NV, Denmark
Jeppesen, Lone, Virum, Denmark
Pettersson, Ingrid, Frederiksberg, Denmark

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001041709	A1	20011115	
APPLICATION INFO.:	US 2001-771217	A1	20010126	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	DK 2000-137	20000128	
	DK 2000-1065	20000707	
	DK 2000-1593	20001025	
	US 2000-181056	20000208	(60)
	US 2000-217903	20000713	(60)
	US 2000-245370	20001102	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY, 10174-6401
NUMBER OF CLAIMS: 80
EXEMPLARY CLAIM: 1
LINE COUNT: 3279
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of formula (I) ##STR1##

The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 13 USPATFULL
ACCESSION NUMBER: 2001:131323 USPATFULL
TITLE: Compounds, their preparation and use
INVENTOR(S): Sauerberg, Per, Farum, Denmark
Murray, Anthony, Hellerup, Denmark
Jeppesen, Lone, Virum, Denmark
Bury, Paul Stanley, K.o slashed.benhavn NV, Denmark
Pettersson, Ingrid, Frederiksberg, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274608	B1	20010814
APPLICATION INFO.:	US 2000-551700		20000418 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-532	19990420
	US 1999-134972	19990520 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Green, Esq., Reza, Gregg, Esq., Valeta A.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel compounds of formula I ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, L, X and Y are as defined in the specification. These compounds are useful in the treatment of conditions
mediated by nuclear receptors, in particular the Retinoid X Receptor (RXR) and the Peroxisome Proliferator-Activated Receptor (PPAR) families. Such conditions include diabetes and obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 13 USPATFULL
ACCESSION NUMBER: 2001:116983 USPATFULL
TITLE: Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
INVENTOR(S): Dasseux, Jean-Louis, Isoldestr. 27, Mannheim, Germany, Federal Republic of D-68199
Sekul, Renate, Wichernstr. 13, Ladenburg, Germany, Federal Republic of D-68526
Buttner, Klaus, Eichendorffstr. 6, Epfenbach, Germany, Federal Republic of D-74925
Cornut, Isabelle, Meisenweg 10, Edingen-Neckarhausen, Germany, Federal Republic of D-68535
Metz, Gunther, Lessingstr. 14, Edingen-Neckarhausen, Germany, Federal Republic of D-68535

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6265377	B1	20010724
APPLICATION INFO.:	US 1999-465719		19991217 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-940093, filed on 29 Sep 1997, now patented, Pat. No. US 6037323
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 11 Drawing Page(s)

blessing/09829026

LINE COUNT: 4541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to **treat** a variety of disorders associated with **dyslipidemia**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 13 USPATFULL
ACCESSION NUMBER: 2001:105025 USPATFULL
TITLE: COMBINATIONS OF **HMG-COA REDUCTASE INHIBITORS** AND NICOTINIC ACID AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT
INVENTOR(S): BOVA, DAVID J., HOLLYWOOD, FL, United States
DUNNE, JOSEPHINE, PLANTATION, FL, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001006644	A1	20010705	
APPLICATION INFO.:	US 1997-903871	A1	19970731	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PETER J MANSO, AKERMAN, SENTERFITT, EIDSON, LAS OLAS CENTRE, SUITE 950, 450 EAST LAS OLAS BOULEVARD, FORT LAUDERDALE, FL, 333012227
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
LINE COUNT: 2260
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an **HMG-CoA reductase inhibitor**, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an **HMG-CoA reductase inhibitor** for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixtures thereof, and (3) a swelling agent to form a sustained release **composition** for extended release of the nicotinic acid or nicotinic acid compound or

mixtures thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a **composition** for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an **HMG-CoA reductase inhibitor** in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compounds to provoke flushing reactions in individuals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 13 USPATFULL

ACCESSION NUMBER:	2000:41011 USPATFULL
TITLE:	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
INVENTOR(S):	Dasseux, Jean-Louis, Isoldestr. 27, Mannheim D-68199, Germany, Federal Republic of Sekul, Renate, Wichernstr. 13, Ladenburg D-68526, Germany, Federal Republic of Buttner, Klaus, Eichendorffstr. 6, Epfenbach D-74925, Germany, Federal Republic of Cornut, Isabelle, Meisenweg 10, Edingen-Neckarhausen D-68535, Germany, Federal Republic of Metz, Gunther, Lessingstr. 14, Edingen-Neckarhausen D-68535, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Dasseux, Jean-Louis, United States (non-U.S. individual) Sekul, Renate, Germany, Federal Republic of (non-U.S. individual) Buttner, Klaus, Germany, Federal Republic of (non-U.S. individual) Cornut, Isabelle, Germany, Federal Republic of (non-U.S. individual) Metz, Gunther, Germany, Federal Republic of (non-U.S. individual) DuFourcq, Jean, France (non-U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046166		20000404
APPLICATION INFO.:	US 1997-940096		19970929 (8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Tsang, Cecilia J.
ASSISTANT EXAMINER:	Borin, Michael
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP
NUMBER OF CLAIMS:	49
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT:	6286

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The

peptides and peptide analogues are useful to **treat** a variety of disorders associated with **dyslipidemia**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 13 USPATFULL

ACCESSION NUMBER:	2000:31397 USPATFULL
TITLE:	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
INVENTOR(S):	Dasseux, Jean-Louis, Isoldestr. 27, Mannheim, Germany, Federal Republic of D-68199 Sekul, Renate, Winchernstr. 13, Ladenburg, Germany, Federal Republic of D-68526 Buttner, Klaus, Eichendorffstr. 6, Epfenbach, Germany, Federal Republic of D-74925 Cornut, Isabelle, Meisenweg 10, Edingen-Neckarhausen, Germany, Federal Republic of Metz, Gunther, Lessingstr. 14, Edingen-Neckarhausen, Germany, Federal Republic of D-68535
PATENT ASSIGNEE(S):	Dasseux, Jean-Louis, Germany, Federal Republic of (non-U.S. individual) Sekul, Renate, Germany, Federal Republic of (non-U.S. individual) Buttner, Klaus, Germany, Federal Republic of (non-U.S. individual) Cornut, Isabelle, Germany, Federal Republic of (non-U.S. individual) Metz, Gunther, Germany, Federal Republic of (non-U.S. individual)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6037323		20000314	
APPLICATION INFO.:	US 1997-940093		19970929	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Russell, Jeffrey E.
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP
NUMBER OF CLAIMS:	54
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT:	6460

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to **treat** a variety of disorders associated with **dyslipidemia**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 13 USPATFULL

ACCESSION NUMBER:	1999:166966 USPATFULL
TITLE:	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
INVENTOR(S):	Dasseux, Jean-Louis, Mannheim, Germany, Federal Republic of Sekul, Renate, Ladenburg, Germany, Federal Republic of

Buttner, Klaus, Epfenbach, Germany, Federal Republic of
Cornut, Isabelle, Edingen-Neckarhausen, Germany, Federal Republic of
Metz, Gunther, Edingen-Neckarhausen, Germany, Federal Republic of
Dufourcq, Jean, Pessac, France

PATENT ASSIGNEE(S): Dasseux, J. L., France (non-U.S. individual)
Sekul, R., Germany, Federal Republic of (non-U.S. individual)
Buttner, K., Germany, Federal Republic of (non-U.S. individual)
Cornut, I., France (non-U.S. individual)
Metz, G., Germany, Federal Republic of (non-U.S. individual)
DuFourcq, J., France (non-U.S. individual)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6004925		19991221	
APPLICATION INFO.:	US 1997-940095		19970929	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Celsa, Bennett
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 7180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to **treat** a variety of disorders associated with **dyslipidemia**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 13 USPATFULL
ACCESSION NUMBER: 1999:137273 USPATFULL
TITLE: .beta.-adrenergic agonists
INVENTOR(S): Dow, Robert L., Waterford, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5977124		19991102	
	WO 9635671		19961114	
APPLICATION INFO.:	US 1997-945551		19971104	(8)
	WO 1995-IB344		19950510	
			19971104	PCT 371 date
			19971104	PCT 102(e) date

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Jones, James T.

blessing/09829026

NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB .beta.-adrenergic agonists for the treatment of diseases/conditions such as obesity and diabetes. The compounds have formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, W, X, Y and Z are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 13 USPATFULL
ACCESSION NUMBER: 1999:4701 USPATFULL
TITLE: .beta.-adrenergic agonists
INVENTOR(S): Dow, Robert L., Waterford, CT, United States
Lundy, Kristin M., Groton, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5859044		19990112
APPLICATION INFO.:	US 1997-892381		19970714 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-22827	19960731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kessinger, Ann M.
LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Ronau, Robert T.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to certain compounds of the formula (I) the racemic-enantiomeric mixtures and optical isomers of said compounds,
prodrugs thereof and the pharmaceutically acceptable salts, depicted below, which are .beta.-adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobesity agents. The invention also relates to methods of use for the compounds and to **compositions** containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in animals, e.g., ungulate animals, companion animals, especially dogs, and poultry. The compounds of formula (I) have the following structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 13 USPATFULL
ACCESSION NUMBER: 1998:150974 USPATFULL
TITLE: Heterocyclic .beta.-adrenergic agonists
INVENTOR(S): Dow, Robert L., Groton, CT, United States

blessing/09829026

	Wright, Stephen W., Groton, CT, United States
PATENT ASSIGNEE(S):	Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5843972		19981201	
APPLICATION INFO.:	US 1997-827289		19970328	(8)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1996-15216	19960409	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Clardy, S. Mark
ASSISTANT EXAMINER:	Qazi, Sabiha N.
LEGAL REPRESENTATIVE:	Richardson, Peter C., Benson, Gregg C., Ronau, Robert T.
NUMBER OF CLAIMS:	15
EXEMPLARY CLAIM:	1
LINE COUNT:	2356

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to certain compounds of the formula (I) the racemic-enantiomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts or prodrugs thereof, depicted below, which are .beta.-adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobesity agents. More specifically, the compounds of the instant invention are selective agonists of .beta..sub.3 -adrenergic receptor. The invention also relates to methods of use for the compounds and to pharmaceutical **compositions** containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in animals, e.g., ungulate animals, companion animals and poultry. The compounds have the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 13 USPATFULL

ACCESSION NUMBER:	97:38543 USPATFULL
TITLE:	.beta..sub.3 -Adrenoceptor agonists and antagonists for the **treatment** of intestinal motility disorders, depression, prostate disease and **dyslipidemia**
INVENTOR(S):	Kreutter, David K., Madison, CT, United States Dow, Robert L., Waterford, CT, United States
PATENT ASSIGNEE(S):	Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5627200		19970506	
APPLICATION INFO.:	US 1994-312027		19940926	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Spivack, Phyllis G.

blessing/09829026

LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Butterfield, Garth C.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1900
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods for **treating** intestinal motility disorders, intestinal ulcerations, including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis, and gastrointestinal ulcerations, depression, prostate disease and **dyslipidemia** by administering a .beta..sub.3 -adrenoceptor antagonist or agonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Search Results -

Term	Documents
(9 AND 8).USPT,PGPB,JPAB,EPAB,DWPI.	14

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Refine Search: `19 and 18` Clear

Search History

Today's Date: 1/5/2002

DB Name	Query	Hit Count	Set Name
USPT,PGPB,JPAB,EPAB,DWPI	19 and 18	14	L10
USPT,PGPB,JPAB,EPAB,DWPI	dyslipidemia	515	L9
USPT,PGPB,JPAB,EPAB,DWPI	17 and 14 and 15	66	L8
USPT,PGPB,JPAB,EPAB,DWPI	11 or 12 or 13	1696	L7
USPT,PGPB,JPAB,EPAB,DWPI	polynoxylin	6	L6
USPT,PGPB,JPAB,EPAB,DWPI	polyvinylpyrrolidone or PVP or polyvinyl pyrrolidone	54937	L5
USPT,PGPB,JPAB,EPAB,DWPI	cholestyramine	1074	L4
USPT,PGPB,JPAB,EPAB,DWPI	HMG-CoA reductase inhibitor	1196	L3
USPT,PGPB,JPAB,EPAB,DWPI	atorvastatin	251	L2
USPT,PGPB,JPAB,EPAB,DWPI	pravastatin	765	L1

US-PAT-NO: 5627200
DOCUMENT-IDENTIFIER: US 5627200 A Print

TITLE: .beta..sub.3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia

DATE-ISSUED: May 6, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kreutter; David K.	Madison	CT		
Dow; Robert L.	Waterford	CT		

US-CL-CURRENT: 514/367; 514/2, 514/255.05, 514/256, 514/269, 514/272, 514/273, 514/274, 514/338, 514/339, 514/375, 514/397, 514/398, 514/399, 514/443, 514/469, 514/470

ABSTRACT:

This invention relates to methods for treating intestinal motility disorders, intestinal ulcerations, including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis, and gastrointestinal ulcerations, depression, prostate disease and dyslipidemia by administering a .beta..sub.3 -adrenoceptor antagonist or agonist.

6 Claims, 0 Drawing figures Exemplary Claim Number: 1

US-PAT-NO: 5843972
DOCUMENT-IDENTIFIER: US 5843972 A

TITLE: Heterocyclic .beta.-adrenergic agonists

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dow; Robert L.	Groton	CT		
Wright; Stephen W.	Groton	CT		

US-CL-CURRENT: 514/367; 514/256, 514/258, 514/365, 514/372, 514/373, 514/374, 514/375, 514/415, 514/443, 514/444, 514/469, 544/253, 548/152, 548/217, 548/237, 549/49, 549/491, 549/492, 549/58

ABSTRACT:

The present invention relates to certain compounds of the formula (I) the racemic-enantiomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts or prodrugs thereof, depicted below, which are .beta.-adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobesity agents. More specifically, the compounds of the instant invention are selective agonists of .beta..sub.3 -adrenergic receptor. The invention also relates to methods of use for the compounds and to pharmaceutical compositions containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in animals, e.g., ungulate animals, companion animals and poultry. The compounds have the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z are as defined in the specification.

15 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWMC | Draw Desc | Image

---

☐ 14. Document ID: US 5627200 A

L10: Entry 14 of 14 File: USPT May 6, 1997

WEST

Generate Collection

Search Results - Record(s) 1 through 14 of 14 returned.

☐ 1. Document ID: US 20020002149 A1

L10: Entry 1 of 14 File: PGPB Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020002149
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020002149 A1

TITLE: Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bayly, Christopher	Beaconsfield		CA	
Ohkubo, Mitsuru	Ushiki		JP	

US-CL-CURRENT: 514/117; 514/126, 558/196

ABSTRACT:

The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. 1

The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc | Image

☐ 2. Document ID: US 20010041709 A1

L10: Entry 2 of 14 File: PGPB Nov 15, 2001

PGPUB-DOCUMENT-NUMBER: 20010041709
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010041709 A1

TITLE: New compounds, their preparation and use

PUBLICATION-DATE: November 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mogensen, John Patrick	Herlev		DK	
Sauerberg, Per	Farum		DK	
Bury, Paul Stanley	Kobenhavn NV		DK	
Jeppesen, Lone	Virum		DK	
Pettersson, Ingrid	Frederiksberg		DK	

US-CL-CURRENT: 514/277; 514/408, 514/521, 514/532, 514/534, 546/335, 546/341, 548/561, 548/572, 558/441, 560/37, 560/55

ABSTRACT:

The present invention relates to compounds of formula (I) 1

The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

☐ 3. Document ID: US 20010006644 A1

L10: Entry 3 of 14 File: PGPB Jul 5, 2001

PGPUB-DOCUMENT-NUMBER: 20010006644
PGPUB-FILING-TYPE: new-utility
DOCUMENT-IDENTIFIER: US 20010006644 A1

TITLE: COMBINATIONS OF HMG-COA REDUCTASE INHIBITORS AND NICOTINIC ACID AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT

PUBLICATION-DATE: July 5, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BOVA, DAVID J.	HOLLYWOOD	FL	US	
DUNNE, JOSEPHINE	PLANTATION	FL	US	

US-CL-CURRENT: 424/400

ABSTRACT:

The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixtures thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixtures thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compounds to provoke flushing reactions in individuals.

☐ 4. Document ID: US 6329341 B1

L10: Entry 4 of 14 File: USPT Dec 11, 2001

US-PAT-NO: 6329341
DOCUMENT-IDENTIFIER: US 6329341 B1

TITLE: Method of treating septic shock

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dasseux; Jean-Louis	Mannheim			DEX
Sekul; Renate	Ladenburg			DEX
Buttner; Klaus	Epfenbach			DEX
Cornut; Isabelle	Edingen-Neckarhausen			DEX
Metz; Gunther	Edingen-Neckarhausen			DEX
Dufourcq; Jean	Pessac			FRX

US-CL-CURRENT: 514/13; 514/12, 514/2, 530/300, 530/324, 530/325, 530/326

ABSTRACT:

The present invention provides peptides and petptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.

21 Claims, 11 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 21

☐ 5. Document ID: US 6274608 B1

L10: Entry 5 of 14 File: USPT Aug 14, 2001

US-PAT-NO: 6274608
DOCUMENT-IDENTIFIER: US 6274608 B1

TITLE: Compounds, their preparation and use

DATE-ISSUED: August 14, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sauerberg; Per	Farum			DKX
Murray; Anthony	Hellerup			DKX
Jeppesen; Lone	Virum			DKX
Bury; Paul Stanley	K.o slashed.benhavn NV			DKX
Pettersson; Ingrid	Frederiksberg			DKX

US-CL-CURRENT: 514/369; 514/543, 514/569, 548/183, 560/56, 562/460

ABSTRACT:

Disclosed are novel compounds of formula I ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, L, X and Y are as defined in the specification. These compounds are useful in the treatment of conditions mediated by nuclear receptors, in particular the Retinoid X Receptor (RXR) and the Peroxisome Proliferator-Activated Receptor (PPAR) families. Such conditions include diabetes and obesity.

18 Claims, 0 Drawing figures Exemplary Claim Number: 1

---

6. Document ID: US 6265377 B1

L10: Entry 6 of 14 File: USPT Jul 24, 2001

US-PAT-NO: 6265377
DOCUMENT-IDENTIFIER: US 6265377 B1

TITLE: Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

DATE-ISSUED: July 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dasseux; Jean-Louis	Mannheim			DEX
Sekul; Renate	Ladenburg			DEX
Buttner; Klaus	Epfenbach			DEX
Cornut; Isabelle	Edingen-Neckarhausen			DEX
Metz; Gunther	Edingen-Neckarhausen			DEX

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 530/324, 530/326, 530/327, 530/328

ABSTRACT:

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.

48 Claims, 22 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Drawi Desc | Image

---

7. Document ID: US 6262118 B1

L10: Entry 7 of 14 File: USPT Jul 17, 2001

US-PAT-NO: 6262118
DOCUMENT-IDENTIFIER: US 6262118 B1

TITLE: Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luskey; Kenneth L.	Saratoga	CA		
Luo; Jian	Brisbane	CA		

US-CL-CURRENT: 514/559

ABSTRACT:

The present invention provides the use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.

11 Claims, 15 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Drawi Desc | Image

8. Document ID: US 6046166 A

L10: Entry 8 of 14 File: USPT Apr 4, 2000

US-PAT-NO: 6046166
DOCUMENT-IDENTIFIER: US 6046166 A

TITLE: Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

DATE-ISSUED: April 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dasseux; Jean-Louis	Mannheim D-68199			DEX
Sekul; Renate	Ladenburg D-68526			DEX
Buttner; Klaus	Epfenbach D-74925			DEX
Cornut; Isabelle	Edingen-Neckarhausen D-68535			DEX
Metz; Gunther	Edingen-Neckarhausen D-68535			DEX

US-CL-CURRENT: 514/13; 435/69.1, 514/12, 514/2, 530/324, 530/325, 530/326, 930/10, 930/30

ABSTRACT:

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.

49 Claims, 23 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

9. Document ID: US 6037323 A

L10: Entry 9 of 14 File: USPT Mar 14, 2000

US-PAT-NO: 6037323
DOCUMENT-IDENTIFIER: US 6037323 A

TITLE: Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

DATE-ISSUED: March 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dasseux; Jean-Louis	Mannheim			DEX
Sekul; Renate	Ladenburg			DEX
Buttner; Klaus	Epfenbach			DEX
Cornut; Isabelle	Edingen-Neckarhausen			DEX
Metz; Gunther	Edingen-Neckarhausen			DEX

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 530/324, 530/326, 530/327, 530/328

ABSTRACT:

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.

54 Claims, 22 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

10. Document ID: US 6004925 A

L10: Entry 10 of 14 File: USPT Dec 21, 1999

US-PAT-NO: 6004925
DOCUMENT-IDENTIFIER: US 6004925 A

TITLE: Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dasseux; Jean-Louis	Mannheim			DEX
Sekul; Renate	Ladenburg			DEX
Buttner; Klaus	Epfenbach			DEX
Cornut; Isabelle	Edingen-Neckarhausen			DEX
Metz; Gunther	Edingen-Neckarhausen			DEX
Dufourcq; Jean	Pessac			FRX

US-CL-CURRENT: 514/2; 514/12, 514/13, 530/300, 530/324, 530/325, 530/326

ABSTRACT:

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.

58 Claims, 11 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 21

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

---

11. Document ID: US 5977124 A

L10: Entry 11 of 14 File: USPT Nov 2, 1999

US-PAT-NO: 5977124
DOCUMENT-IDENTIFIER: US 5977124 A

TITLE: .beta.-adrenergic agonists

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dow; Robert L.	Waterford	CT		

US-CL-CURRENT: 514/272; 514/352, 544/332, 546/312, 548/110, 548/252, 548/253, 556/416

ABSTRACT:

.beta.-adrenergic agonists for the treatment of diseases/conditions such as obesity and diabetes. The compounds have formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, W, X, Y and Z are as defined in the specification.

21 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

12. Document ID: US 5859044 A

L10: Entry 12 of 14 File: USPT Jan 12, 1999

US-PAT-NO: 5859044
DOCUMENT-IDENTIFIER: US 5859044 A

TITLE: .beta.-adrenergic agonists

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dow; Robert L.	Waterford	CT		
Lundy; Kristin M.	Groton	CT		

US-CL-CURRENT: 514/419; 548/492

ABSTRACT:

The present invention relates to certain compounds of the formula (I) the racemic-enantiomeric mixtures and optical isomers of said compounds, prodrugs thereof and the pharmaceutically acceptable salts, depicted below, which are .beta.-adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobesity agents. The invention also relates to methods of use for the compounds and to compositions containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in animals, e.g., ungulate animals, companion animals, especially dogs, and poultry. The compounds of formula (I) have the following structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification.

20 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw Desc | Image

13. Document ID: US 5843972 A

L10: Entry 13 of 14 File: USPT Dec 1, 1998